Implication of TNF-Related Apoptosis-Inducing Ligand in Inflammatory Intestinal Epithelial Lesions

Gastroenterology

Volumn 130, Issue 7, 2006, Pages 1962-1974

  Begue, Bernadette ^a   Wajant, Harald ^b   Bambou, Jean Christophe ^a   Dubuquoy, Laurent ^c   Siegmund, Daniela ^b   Beaulieu, Jean François ^d   Canioni, Danielle ^e   Berrebi, Dominique ^f   Brousse, Nicole ^a,e   Desreumaux, Pierre ^c   Schmitz, Jacques ^a,e   Lentze, Michael J ^g   Goulet, Oliver ^a,e   Cerf Bensussan, Nadine ^a   Ruemmele, Frank M ^a,e,g  

^a INSERM   (France)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIV LILLE   (France)

^d UNIVERSITÉ DE SHERBROOKE   (Canada)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f HÔPITAL ROBERT DEBRÉ   (France)

^g University Children's Medical Center   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE RECRUITMENT DOMAIN PROTEIN 15; DEATH RECEPTOR; DEATH RECEPTOR 5; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; LIPOCORTIN 5; MESSENGER RNA; PROTEIN; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CELL LINE; CELL STRAIN CACO 2; COLON; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; ILEITIS; ILEUM; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTESTINE EPITHELIUM; LAMINA PROPRIA; LYMPHOCYTE; ORGAN CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 33744546642     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.03.022     Document Type: Article

References (47)

1. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 347 (2002) 417-429
2. Shanahan F. Crohn's disease. Lancet 359 (2002) 62-69
3. Bouma G., and Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3 (2003) 521-533
4. Kontoyiannis D., Pasparakis M., Pizarro T.T., Cominelli F., and Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements. implications for joint and gut-associated immunopathologies. Immunity 10 (1999) 387-398
5. Neurath M.F., Fuss I., Pasparakis M., Alexopoulou L., Haralambous S., Meyer zum Buschenfelde K.H., Strober W., and Kollias G. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 27 (1997) 1743-1750
6. Braegger C.P., Nicholls S., Murch S.H., Stephens S., and MacDonald T.T. Tumour necrosis factor α in stool as a marker of intestinal inflammation. Lancet 339 (1992) 89-91
7. Ruemmele F.M., Dionne S., Levy E., and Seidman E.G. TNF-α-induced IEC-6 cell apoptosis requires activation of ICE-caspases, whereas complete inhibition of the caspase-cascade led to necrotic cell death. Biochem Biophys Res Commun 260 (1999) 159-166
8. Garside P., Bunce C., Tomlinson R.C., et al. Analysis of enteropathy induced by tumour necrosis factor α. Cytokine 5 (1993) 24-30
9. Strater J., Wellisch I., Riedl S., Walczak H., Koretz K., Tandara A., Krammer P.H., and Moller P. CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells. a possible role in ulcerative colitis. Gastroenterology 113 (1997) 160-167
10. Merger M., Viney J.L., Borojevic R., Steele-Norwood D., Zhou P., Clark D.A., Riddell R., Maric R., Podack E.R., and Croitoru K. Defining the roles of perforin, Fas/FasL, and tumour necrosis factor α in T-cell-induced mucosal damage in the mouse intestine. Gut 51 (2002) 155-163
11. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., and Smith C.A. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
12. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., and Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271 (1996) 12687-12690
13. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., and Dixit V.M. The receptor for the cytotoxic ligand TRAIL. Science 276 (1997) 111-113
14. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., Chin W., Jones J., Woodward A., Le T., Smith C., Smolak P., Goodwin R.G., Rauch C.T., Schuh J.C., and Lynch D.H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5 (1999) 157-163
15. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., DeForge L., Koumenis I.L., Lewis D., Harris L., Bussiere J., Koeppen H., Shahrokh Z., and Schwall R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104 (1999) 155-162
16. Walczak H., and Krammer P.H. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 256 (2000) 58-66
17. LeBlanc H.N., and Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10 (2003) 66-75
18. Schneider P., Thome M., Burns K., Bodmer J.L., Hofmann K., Kataoka T., Holler N., and Tschopp J. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB. Immunity 7 (1997) 831-836
19. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., Ramakrishnan L., Gray C.L., Baker K., Wood W.I., Goddard A.D., Godowski P., and Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 (1997) 818-821
20. Degli-Esposti M.A., Dougall W.C., Smolak P.J., Waugh J.Y., Smith C.A., and Goodwin R.G. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7 (1997) 813-820
21. Song K., Chen Y., Goke R., Wilmen A., Seidel C., Goke A., Hilliard B., and Chen Y. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 191 (2000) 1095-1104
22. Lamhamedi-Cherradi S.E., Zheng S.J., Maguschak K.A., Peschon J., and Chen Y.H. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat Immunol 4 (2003) 255-260
23. Lunemann J.D., Waiczies S., Ehrlich S., Wendling U., Seeger B., Kamradt T., and Zipp F. Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J Immunol 168 (2002) 4881-4888
24. Diehl G.E., Yue H.H., Hsieh K., Kuang A.A., Ho M., et al. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 21 (2004) 877-989
25. Strater J., Walczak H., Pukrop T., Von Muller L., Hasel C., Kornmann M., Mertens T., and Moller P. TRAIL and its receptors in the colonic epithelium. a putative role in the defense of viral infections. Gastroenterology 122 (2002) 659-666
26. Perreault N., and Beaulieu J.F. Use of the dissociating enzyme thermolysin to generate viable human normal intestinal epithelial cell cultures. Exp Cell Res 224 (1996) 254-264
27. Ruemmele F.M., Beaulieu J.F., Dionne S., Levy E., Seidman E.G., Cerf-Bensussan N., and Lentze M.J. LPS-modulation of normal enterocyte turnover via toll-like receptors is mediated by endogenously produced tumor necrosis factor-α. Gut 51 (2002) 842-848
28. Cellier C., Patey N., Mauvieux L., et al. Abnormal intestinal intraepithelial lymphocytes in refractory sprue. Gastroenterology 114 (1998) 471-481
29. Ruemmele F.M., Russo P., Beaulieu J.-F., Dionne S., Levy E., Lentze M.J., and Seidman E.G. Susceptibility to FAS-induced apoptosis in human non-tumoral enterocytes-the role of co-stimulatory factors. J Cell Physiol 181 (1999) 45-54
30. Philippe D., Dubuquoy L., Groux H., Brun V., Chuoi-Mariot M.T., Gaveriaux-Ruff C., Colombel J.F., Kieffer B.L., and Desreumaux P. Anti-inflammatory properties of the μ opioid receptor support its use in the treatment of colon inflammation. J Clin Invest 111 (2003) 1329-1338
31. Siegmund D., Hausser A., Peters N., Scheurich P., and Wajant H. Tumor necrosis factor (TNF) and phorbol ester induce TNF-related apoptosis-inducing ligand (TRAIL) under critical involvement of NF-κB essential modulator (NEMO)/IKKγ. J Biol Chem 276 (2001) 43708-43712
32. Philpott D.J., Yamaoka S., Israel A., and Sansonetti P.J. Invasive Shigella flexneri activates NF-κB through a lipopolysaccharide-dependent innate intracellular response and leads to IL-8 expression in epithelial cells. J Immunol 165 (2000) 903-914
33. Koornstra J.J., Kleibeuker J.H., van Geelen C.M., Rijcken F.E., Hollema H., de Vries E.G., and de Jong S. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 200 (2003) 327-335
34. Hu W.H., Johnson H., and Shu H.B. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-κB and JNK activation and apoptosis through distinct pathways. J Biol Chem 274 (1999) 30603-30610
35. Lin Y., Devin A., Cook A., Keane M.M., Kelliher M., Lipkowitz S., and Liu Z.G. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IκB kinase and c-Jun N-terminal kinase. Mol Cell Biol 20 (2000) 6638-6645
36. MacFarlane M. TRAIL-induced signalling and apoptosis. Toxicol Lett 139 (2003) 89-97
37. Girardin S.E., Boneca I.G., Viala J., Chamaillard M., Labigne A., Thomas G., Philpott D.J., and Sansonetti P.J. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 278 (2003) 8869-8872
38. Begue B., Dumant C., Bambou J.C., Beaulieu J.F., Giovannini M., Cerf-Bensussan N., Philpott D., and Ruemmele F.M. Crohn's disease as an innate immune defect-the critical role of CARD15 in intestinal antibacterial defence. WCPGHN, 2004, Paris. J Pediatr Gastroenterol Nutr 39 (2004) S48
39. Ichikawa K., Liu W., Fleck M., Zhang H., Zhao L., Ohtsuka T., Wang Z., Liu D., Mountz J.D., Ohtsuki M., Koopman W.J., Kimberly R., and Zhou T. TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol 171 (2003) 1061-1069
40. Ruemmele F.M., Beaulieu J.F., O'Connell J., Bennet M.W., Seidman E.G., and Lentze M.J. The susceptibility to Fas-induced apoptosis in normal enterocytes is regulated on the level of cIAP1 and 2. Biochem Biophys Res Commun 290 (2002) 1308-1314
41. Leverkus M., Sprick M.R., Wachter T., Mengling T., Baumann B., Serfling E., Brocker E.B., Goebeler M., Neumann M., and Walczak H. Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. Mol Cell Biol 23 (2003) 777-790
42. Du C., Fang M., Li Y., Li L., and Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102 (2000) 33-42
43. Li L., Thomas R.M., Suzuki H., De Brabander J.K., Wang X., and Harran P.G. A small molecule Smac mimic potentiates TRAIL- and TNF-α-mediated cell death. Science 305 (2004) 1471-1474
44. Liston P., Fong W.G., Kelly N.L., Toji S., Miyazaki T., Conte D., Tamai K., Craig C.G., McBurney M.W., and Korneluk R.G. Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat Cell Biol 3 (2001) 128-133
45. Sato K., Hida S., Takayanagi H., Yokochi T., Kayagaki N., Takeda K., Yagita H., Okumura K., Tanaka N., Taniguchi T., and Ogasawara K. Antiviral response by natural killer cells through TRAIL gene induction by IFN-α/β. Eur J Immunol 31 (2001) 3138-3146
46. Ichikawa K., Liu W., Zhao L., Wang Z., Liu D., Ohtsuka T., Zhang H., Mountz J.D., Koopman W.J., Kimberly R.P., and Zhou T. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7 (2001) 954-960
47. Mundt B., Kuhnel F., Zender L., Paul Y., Tillmann H., Trautwein C., Manns M.P., and Kubicka S. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J 17 (2003) 94-96